Samyang Biopharmaceuticals' U.S. subsidiary, Samyang Biopharm USA, is pushing to develop its cancer immunotherapy drug candidate, SYB-010, through global open innovation.Samyang Biopharm USA recently signed an agreement with the Spanish National Research Council, the largest public research institut
Researchers at Bundang CHA Hospital and Chaum Life Center have found a relationship between urine organic acids and metabolic syndrome.“It is often difficult for people with metabolic syndrome to know which metabolic problem they have,” the hospital said.Therefore, the team -- led by Professors Ham
Covid-19 survivors can develop sufficient antibodies by receiving a single dose of a Covid-19 vaccine, a Korean study showed.According to the study, people who recovered from Covid-19 infection could enjoy a full protection effect with only one-time vaccination.The study could back up a proposal tha
The first CAR-T therapy, Kymriah (ingredient: tisagenlecleucel), failed to pass the review of a panel at the Health Insurance Review and Assessment Service (HIRA) due to its hefty price tag of 500 million won ($430,884).According to an official at HIRA, the agency’s cancer drugs benefit appraisal co
HLB said the company would present the two interim results of combination treatment of its rivoceranib with immune-oncology and cytotoxic antineoplastic drugs at the online World Conference on Lung Cancer (WCLC) 2021 on Sept. 13.The clinical results showed a 40 percent overall response rate (ORR), 9
Researchers at the Korea Institute of Science and Technology (KIST) have developed an artificial intelligence technology that generates computed tomography based on magnetic resonance imaging images.The team, led by Doctor Kim Hyung-min of the Bionics Research Center at KIST, hopes that the technolo
Hanall Biopharma said its Chinese partner, Harbour BioMed, has received approval from China's National Medical Products Administration (NMPA) to conduct a phase 2 clinical trial of HL161 for chronic inflammatory demyelinating polyneuropathy.Harbour BioMed signed an agreement with Hanall Biopharma in
Voronoi said that it has licensed out its autoimmune disease treatment program to Brickell Biotech.Under the accord, Voronoi will receive a down payment of $5 million and can receive up to $323.5 million depending on the development progress of the treatment candidate.The candidate inhibits the diff
Pfizer Korea said Thursday that the Ministry of Health and Welfare would begin to reimburse Somavert, its acromegaly treatment, from this month.According to the current standard, the health authorities reimburse Somarvert to patients over 18 with acromegaly who have received surgery and radiation th
Innovative AI healthcare companies are boasting their technologies at the 77th Korean Congress of Radiology 2021 (KCR 2021), offering a chance to experience AI solutions on-site and presenting how radiologists can use those solutions.KCR is one of the leading radiology conferences in Asia hosted by
The following article has been provided by Vetter Pharma International GmbH as part of its public relations activities. Korea Biomedical Review has no relationship with and bears no responsibility for the contents and opinions in it. – Ed. In the health care industry, changes are occurring at a rapi
Domestic companies are jumping into the fray to develop therapies for stroke, like their multinational counterparts who have struggled to see significant results in their clinical trials.Actilyse (ingredient: alteplase), a tissue plasminogen activator (tPA) developed by Boehringer Ingelheim, is the
Health authorities said that if the six million doses of Moderna's Covid-19 vaccine do not arrive in time, it could be hard to achieve the government's immunization goals.Moderna had said that it would supply less than half of the 8.5 million doses scheduled for supply in August due to a production
GSK and the German biopharmaceutical company CureVac said their second-generation mRNA Covid-19 vaccine demonstrated an improved immune response than the first generation, marking higher neutralizing antibody capacity against the variant strains.The preclinical study assessed the Covid-19 immune res
Korean pharmaceutical companies are actively conducting R&D to secure a share in the 21 trillion won ($18.1 billion) global gastric acid blocker market.In foreign markets, they are particularly focusing on commercializing potassium-competitive acid blockers (P-CABs), the next-generation treatment fo
Jazz Pharmaceuticals, SK Biopharmaceuticals’ U.S. partner, said that it has received sales approval for Sunosi (Ingredient: solriamfetol), a new sleep disorder drug, from the Canadian health authorities.With the approval, hospitals can prescribe the drug to treat adult patients suffering from excess
Boryung Pharmaceutical said Wednesday that it has launched Onbevzi, a biosimilar for Avastin (Ingredient: bevacizumab) developed by Samsung Bioepis in Korea.The launch comes after Boryung acquired exclusive sales rights in Korea for Onbevzi from Samsung in May of this year. According to the company,
The National Health Insurance Service (NHIS) said that the reimbursement claims for anticancer drugs last year amounted to about 1.91 trillion won ($1.6 billion), accounting for 9.3 percent of the total drug reimbursement payouts of 20.3 trillion won.According to the NHIS, medical expenses for healt
Vuno said Wednesday that its artificial intelligence-based solution reading chest X-ray image, VUNO Med-Chest X-ray, has obtained marketing approval from the Taiwan Food and Drug Administration (TFDA).The company signed an exclusive sales agreement with Taiwan’s CHC Healthcare Group (CHC), the large
The Korea Exchange granted a one-year grace period for Kolon TissueGene, delaying the decision whether to delist the company from the Kosdaq market.Last year, the government revoked the permit for the company’s gene therapy Invossa-K over mislabeling an ingredient and falsely reporting it to the reg